Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Ficlatuzumab (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions
- 07 Dec 2017 Status changed from not yet recruiting to recruiting, according to an AVEO Oncology media release.
- 04 Dec 2017 Planned initiation date changed from 30 Nov 2017 to 30 Dec 2017.
- 25 Oct 2017 New trial record